NRSN (NeuroSense Therapeutics) Beginning Cash Position: $0.70 Mil (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Beginning Cash Position?

NeuroSense Therapeutics NRSN -1.82% 31 Beginning Cash Position is $0.70 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2025 was $0.70 Mil.

NeuroSense Therapeutics's quarterly Beginning Cash Position increased from Dec. 2024 ($-0.04 Mil) to Jun. 2025 ($3.38 Mil) but then declined from Jun. 2025 ($3.38 Mil) to Dec. 2025 ($0.70 Mil).

NeuroSense Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($3.54 Mil) to Dec. 2024 ($2.64 Mil) but then increased from Dec. 2024 ($2.64 Mil) to Dec. 2025 ($3.38 Mil).

NeuroSense Therapeutics Beginning Cash Position Related Terms

NeuroSense Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Beginning Cash Position Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.70 11.06 3.54 2.64 3.38

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.64 -0.04 3.38 0.70
NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.70 Mil mean?
NeuroSense Therapeutics (NRSN) has a Beginning Cash Position of $0.70 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Beginning Cash Position too high?
NeuroSense Therapeutics' current Beginning Cash Position is $0.70 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Beginning Cash Position compare to SER and PVCT?
NeuroSense Therapeutics' Beginning Cash Position of $0.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Beginning Cash Position is $0.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Beginning Cash Position of $0.70 Mil. The current Beginning Cash Position is $0.70 Mil. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Beginning Cash Position is $0.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price